MEDP vs TMO

For growth investors, Medpace Holdings, Inc.

(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Thermo Fisher Scientific Inc.

(TMO) is the cheapest at 26. 7x versus Medpace Holdings, Inc. at 27. 9x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Medpace Holdings, Inc. wins at 0. 79x versus Thermo Fisher Scientific Inc. 's 9. 02x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +160. 4%, compared to +2. 1% for Thermo Fisher Scientific Inc. (TMO). Over 10 years, the gap is even starker: MEDP returned +1436% versus TMO's +229. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.

(TMO) is the lower-risk stock at 1. 10β versus Medpace Holdings, Inc. 's 1. 26β — meaning MEDP is approximately 15% more volatile than TMO relative to the S&P 500. On balance sheet safety, Medpace Holdings, Inc. (MEDP) carries a lower debt/equity ratio of 55% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Medpace Holdings, Inc.

(MEDP) is pulling ahead at 20. 0% versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). On earnings-per-share growth, the picture is similar: Medpace Holdings, Inc. grew EPS 21. 0% year-over-year, compared to 7. 3% for Thermo Fisher Scientific Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Medpace Holdings, Inc.

(MEDP) is the more profitable company, earning 17. 8% net margin versus 15. 1% for Thermo Fisher Scientific Inc. — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus 18. 2% for TMO. At the gross margin level — before operating expenses — TMO leads at 37. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Medpace Holdings, Inc. (MEDP) is the more undervalued stock at a PEG of 0. 79x versus Thermo Fisher Scientific Inc. 's 9. 02x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 0x forward P/E versus 25. 1x for Medpace Holdings, Inc. — 6. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 4% to $654. 67.

In this comparison, TMO (0.

4% yield) pays a dividend. MEDP does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1436% 10Y return). Both have compounded well over 10 years (MEDP: +1436%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MEDP is a mid-cap high-growth stock; TMO is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.